Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography : results of the HORIZON Pivotal Fracture Trial.
(2010) Osteoporosis International : with other metabolic bone diseases —
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 155.68 KB
Details
- Authors
- Abstract
- Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength.
- Affiliations
Citations
Eastell, R., Lang, T., Boonen, S., Cummings, S., Delmas, P. D., Cauley, J. A., Horowitz, Z., Kerzberg, E., Bianchi, G., Kendler, D., Leung, P., Man, Z., Mesenbrink, P., Eriksen, E. F., & Black, D. M. (2010). Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography : results of the HORIZON Pivotal Fracture Trial. Osteoporosis International : with other metabolic bone diseases. https://doi.org/10.1007/s00198-009-1077-9